A new survey from the supply-chain analysis company revals inefficiencies, inaccurate data and other flaws can be costly in terms of revenue, reputation and patient lives.
Siegfried Holding AG saw higher earnings in the first half of 2017 with cost synergies offsetting the negative impact facility maintenance work had on its API business.
Cancer Genetics’ acquisition of vivoPharm expands its geographical footprint, customer base, and diversifies its business model beyond fee for service, says CEO.
Charles River Laboratories has acquired Brains On-Line in an ongoing effort to deepen its drug discovery capabilities and build out its portfolio through strategic acquisitions.
Biologics contracting drove growth in fiscal Q3 according to Catalent, which predicted the proportion of revenue it generates from large molecule work will continue to increase.
Siegfried saw higher sales in 2016 thanks to the API business it bought from BASF and opening of new plant in China, but profits fell on integration costs and higher taxes.
Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.
Thermo Fisher Scientific, Inc. saw revenue grow 8% in 2016, mostly due to acquisitions of new Chromotography and mass spectrometry tech and expanding its Bioproduction.
Avid Bioservices has reported strong contract manufacturing revenues for its Q2 and is confident a planned third facility will not leave the firm with too much capacity.
Avantor Performance Materials has had its positive rating reiterated by Moody’s just days before its merger with Nusil Technology is expected to complete.
Catalent has more than doubled its biologics business since it went public in 2014, but the sector still represents less than 5% of the CDMO’s revenues.
Charles River says it is capitalising on the growing number of biologics in development, with its manufacturing business seeing double-digit growth led by demand for biosafety and cell banking services.
Cambrex has said it will invest around $20m in its Pharma 4 API facility before the end of the year in an effort to get ahead of the capacity utilisation curve.
A restructuring programme which closed two US facilities and slashed hundreds of jobs has paid off says Amgen, attributing increased margins to better manufacturing efficiencies.
Acquisitions, higher demand for sterile liquid processing and a surge in Thyrosafe orders helped Recipharm offset pricing pressure in Portugal and lower UK sales in Q2.
Parexel has announced its financial results for the third quarter of FY16, which remained strong in spite of the complexities associated with smaller clinical trials.
Quintiles and IMS Health have merged to form Quintiles IMS Holdings, effectively creating one of the world’s largest healthcare information portfolios.
A new single-use bioproduction plant will bring in annual revenues of $40m, says Avid Bioservices which is already eyeing up additional capacity to cope with contract manufacturing demand.
After months of speculation, Charles River Laboratories has decided to move forward with the re-opening of its early-stage research site in Shrewsbury, Massachusetts sometime in the first quarter of 2016.
Consistent Q2 growth for the world’s largest CRO (contract research organization) Quintiles was driven by a spike in the company’s Integrated Healthcare Services (IHS) segment.
CRO (contract research organization) PRA Health Sciences reported in its earnings call on Tuesday that earlier in Q2 it acquired Value Health Solutions (VHS), a clinical development software company, for $2.5m.
US-based contract development and manufacturing organization (CDMO) Patheon has registered with the SEC as part of plans to go public with an IPO that could be worth as much as $100m.
West Pharmaceutical Services expects annual revenues of up to $5m following the US FDA approval of a client’s product which uses West’s Crystal Zenith delivery system.
Although Parexel’s consolidated service revenue increased by only 2% for the quarter, the company reported that its backlog included gross new business wins of $942.4m, which was 5.3% higher than the same quarter as last year.
CRO Quintiles’ recent purchases of oncology and medical device specialist Novella and EHR service firm Encore Health Resources are starting to reap new benefits for the world’s largest CRO, the company reported in its earnings call on Wednesday.
Charles River Laboratories saw only slight growth in revenue compared to the same quarter last year, which was driven by its safety assessment and endotoxin and microbial detection businesses, and double-digit revenue increases from mid-tier biotech clients.
Just two months after Covance shareholders signed off on LabCorp acquiring the company, and all seems to be going according to plan, though financial expectations for the rest of the year were slightly lowered by the diagnostics company.
Nearly a week since Pfizer formally announced its third CRO partner as PPD, the spotlight shifted to Icon as the CRO earns nearly one-third of its revenue from Pfizer.
Aggressive investment in new manufacturing capacity and new initiatives in genomics and cell therapy in 2015 is forcing CRO Wuxi to lower its expectations for 2015, and the lowered projections also seemed to have caused the company’s stock to fall by...
Dublin-based CRO Icon saw its quarterly net revenue, backlog and income rise over the same quarter last year, all of which helped to boost its stock by about 10% on Wednesday.
Covance’s 5% revenue growth and a book-to-bill ratio of 1.3 for the fourth quarter 2014 was better than anticipated and an encouraging sign for LabCorp, an analyst says.
After fending off hostile takeover bids from Valeant for nearly seven months, Allergan is finally agreeing to a takeover, but with Ireland-based Actavis.
Quintiles reported almost 14% growth in revenue, which was largely due to increasing revenue from its Integrated Health Services (IHS), which saw almost 35% quarterly growth.
Weaker demand in Europe and Japan saw revenue from Charles River Laboratories' animal models business decline in Q3, but Argenta and BioFocus boosted discovery sales.
